Advertisement

Heart and Vessels

, Volume 34, Issue 5, pp 755–762 | Cite as

Variations in the eicosapentaenoic acid–arachidonic acid ratio associated with age in acute myocardial infarction patients undergoing primary percutaneous coronary intervention

  • Keisuke Nakabayashi
  • Kentaro JujoEmail author
  • Yuho Furuki
  • Issei Ishida
  • Hiroshi Ando
  • Minoru Shimizu
  • Nobuhisa Hagiwara
  • Katsumi Saito
Original Article
  • 54 Downloads

Abstract

Acute myocardial infarction (AMI) is a life-threatening disease, and its incidence has been increasing even in the young population. Although a low eicosapentaenoic acid (EPA)–arachidonic acid (AA) ratio is associated with an increased risk of coronary artery disease, the effect of age on EPA/AA ratios in AMI patients remains unclear. This study aimed to clarify the independent polyunsaturated fatty acid (PUFA)-related determinants of age in younger and older AMI patients. A total of 153 consecutive patients who underwent primary percutaneous coronary interventions (PCIs) for de novo AMIs were enrolled in this study. Patients’ background data, including PUFA and lipid profiles during PCI, were evaluated retrospectively. The EPA/AA ratio correlated positively with age (r = 0.21; P = 0.011) and increased markedly from age 60 years. Patients aged < 60 years (n = 35) had a lower mean EPA/AA ratio (0.25 ± 0.16) than patients aged ≥ 60 years (n = 118) (0.38 ± 0.25) (P < 0.001). The AA level was more dependent on age than on EPA level (r = − 0.34, P < 0.001 vs. r = 0.12, P = 0.16). The multivariate analysis revealed that a 0.1 EPA/AA ratio increase (odds ratio 1.50; 95% confidence interval 1.09–2.06), body mass index, triglyceride level, and aspirin administration were independently associated with the age stratification of AMI patients. The EPA/AA ratio was higher in younger AMI patients who have undergone primary PCIs than in older patients. Younger population at risk for AMI should be managed with multiple interventions including PUFA profiling.

Keywords

Acute myocardial infarction Coronary artery disease Eicosapentaenoic acid–arachidonic acid ratio Percutaneous coronary intervention Polyunsaturated fatty acids 

Notes

Acknowledgements

We would like to thank Editage (http://www.editage.jp) for English language editing. This study was not supported financially by any company, grant, or fund.

Compliance with ethical standards

Conflict of interest

All authors have no conflicts of interest to declare.

Supplementary material

380_2018_1302_MOESM1_ESM.docx (4.8 mb)
Supplementary material 1 (DOCX 4880 kb)

References

  1. 1.
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists C (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278CrossRefGoogle Scholar
  2. 2.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets I (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435CrossRefGoogle Scholar
  3. 3.
    Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC Jr, Dai D, Hernandez A, Fonarow GC (2009) Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J 157(111–117):e112Google Scholar
  4. 4.
    Alagona P Jr (2009) Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care 15:S65–S73Google Scholar
  5. 5.
    Ninomiya T, Nagata M, Hata J, Hirakawa Y, Ozawa M, Yoshida D, Ohara T, Kishimoto H, Mukai N, Fukuhara M, Kitazono T, Kiyohara Y (2013) Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. Atherosclerosis 231:261–267CrossRefGoogle Scholar
  6. 6.
    Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB (1997) Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 336:1046–1053CrossRefGoogle Scholar
  7. 7.
    Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPAlisI (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369:1090–1098CrossRefGoogle Scholar
  8. 8.
    Ohnishi H, Saito Y (2013) Eicosapentaenoic acid (EPA) reduces cardiovascular events: relationship with the EPA/arachidonic acid ratio. J Atheroscler Thromb 20:861–877CrossRefGoogle Scholar
  9. 9.
    Harris WS, Poston WC, Haddock CK (2007) Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 193:1–10CrossRefGoogle Scholar
  10. 10.
    Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, Shimokawa H, Investigators M-AS (2010) Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI Registry Study. Circ J 74:93–100CrossRefGoogle Scholar
  11. 11.
    Morimoto A, Nishimura R, Suzuki N, Matsudaira T, Taki K, Tsujino D, Miyashita Y, Ebara F, Ishikawa S, Tajima N (2008) Low prevalence of metabolic syndrome and its components in rural Japan. Tohoku J Exp Med 216:69–75CrossRefGoogle Scholar
  12. 12.
    Arita M, Clish CB, Serhan CN (2005) The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun 338:149–157CrossRefGoogle Scholar
  13. 13.
    Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M, Yamamoto M, Shinozaki T, Miyauchi K, Nagao K, Hirayama A, Yoshimura M, Komuro I, Nagai R, Daida H (2014) Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. Am J Cardiol 113:441–445CrossRefGoogle Scholar
  14. 14.
    Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M, Yamamoto M, Shinozaki T, Miyazaki T, Miyauchi K, Nagao K, Hirayama A, Yoshimura M, Komuro I, Nagai R, Daida H (2016) Association between the docosahexaenoic acid to arachidonic acid ratio and acute coronary syndrome: a multicenter observational study. BMC Cardiovasc Disord 16:143CrossRefGoogle Scholar
  15. 15.
    Endo T, Tomita H, Higuma T, Abe N, Kushibiki M, Saitoh S, Yamada M, Yokota T, Echizen T, Yokoyama H, Tateyama S, Suzuki A, Ishida Y, Murakami K, Osanai T, Okumura K (2014) Low serum eicosapentaenoic acid level is a risk for ventricular arrhythmia in patients with acute myocardial infarction: a possible link to J-waves. Heart Vessels 29:847–854CrossRefGoogle Scholar
  16. 16.
    Ueeda M, Doumei T, Takaya Y, Ohnishi N, Takaishi A, Hirohata S, Miyoshi T, Shinohata R, Usui S, Kusachi S (2011) Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of major adverse cardiac events after acute myocardial infarction. Heart Vessels 26:145–152CrossRefGoogle Scholar
  17. 17.
    Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESCAAHAWHFTFftUDoMI, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S (2012) Third universal definition of myocardial infarction. Circulation 126:2020–2035CrossRefGoogle Scholar
  18. 18.
    Fibrinogen Studies C, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D’Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799–1809Google Scholar
  19. 19.
    Juhan-Vague I, Morange P, Christine Alessi M (1999) Fibrinolytic function and coronary risk. Curr Cardiol Rep 1:119–124CrossRefGoogle Scholar
  20. 20.
    Trip MD, Cats VM, van Capelle FJ, Vreeken J (1990) Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322:1549–1554CrossRefGoogle Scholar
  21. 21.
    Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, European Atherosclerosis Society Consensus P (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31:2844–2853CrossRefGoogle Scholar
  22. 22.
    Karadeniz M, Duran M, Akyel A, Yarlioglues M, Ocek AH, Celik IE, Kilic A, Yalcin AA, Ergun G, Murat SN (2015) High sensitive CRP level is associated with intermediate and high syntax score in patients with acute coronary syndrome. Int Heart J 56:377–380CrossRefGoogle Scholar
  23. 23.
    Tani S, Nagao K, Hirayama A (2015) Association of atherosclerosis-related markers and its relationship to n-3 polyunsaturated fatty acids levels with a prevalence of coronary artery disease in an urban area in Japan. Heart Vessels 30:9–19CrossRefGoogle Scholar
  24. 24.
    Shimada T, Kadota K, Eguchi H, Osakada K, Kuwayama A, Ohya M, Miura K, Amano H, Kubo S, Ozaki M, Hyodo Y, Yoshino M, Miyake K, Kawase Y, Ohashi N, Otsuru S, Tasaka H, Habara S, Tada T, Tanaka H, Maruo T, Fuku Y, Katoh H, Fujii S, Goto T, Mitsudo K (2017) Relationship between n-3 Polyunsaturated Fatty Acids and Extent of Vessel Disease in Patients with ST Elevation Myocardial Infarction. Int Heart J 58:868–873CrossRefGoogle Scholar
  25. 25.
    Yanagisawa N, Shimada K, Miyazaki T, Kume A, Kitamura Y, Ichikawa R, Ohmura H, Kiyanagi T, Hiki M, Fukao K, Sumiyoshi K, Hirose K, Matsumori R, Takizawa H, Fujii K, Mokuno H, Inoue N, Daida H (2010) Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. J Atheroscler Thromb 17:285–294CrossRefGoogle Scholar
  26. 26.
    Serikawa T, Miura S, Okabe M, Hongo H, Tokutome M, Yoshikawa T, Takesue K, Adachi S, Osaka K, Matsukawa R, Yanagi D, Nozoe M, Kozai T, Hironaga K, Saku K, Yamamoto Y (2014) Ratio of eicosapentaenoic acid to arachidonic acid is a critical risk factor for acute coronary syndrome in middle-aged older patients as well as younger adult patients. J Cardiol 63:35–40CrossRefGoogle Scholar
  27. 27.
    Yagi S, Aihara K, Fukuda D, Takashima A, Bando M, Hara T, Nishimoto S, Ise T, Kusunose K, Yamaguchi K, Tobiume T, Iwase T, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Akaike M, Sata M (2015) Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome. Nutr J 14:111CrossRefGoogle Scholar
  28. 28.
    Nelson GJ, Kelley DS, Emken EA, Phinney SD, Kyle D, Ferretti A (1997) A human dietary arachidonic acid supplementation study conducted in a metabolic research unit: rationale and design. Lipids 32:415–420CrossRefGoogle Scholar
  29. 29.
    Kusumoto A, Ishikura Y, Kawashima H, Kiso Y, Takai S, Miyazaki M (2007) Effects of arachidonate-enriched triacylglycerol supplementation on serum fatty acids and platelet aggregation in healthy male subjects with a fish diet. Br J Nutr 98:626–635CrossRefGoogle Scholar
  30. 30.
    Canadian Cardiovascular S, American Academy of Family P, American College of C, American Heart A, Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Pearle DL, Sloan MA, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210–247CrossRefGoogle Scholar
  31. 31.
    Meadows TA, Bhatt DL (2007) Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100:1261–1275CrossRefGoogle Scholar
  32. 32.
    Fintel DJ (2012) Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Health Risk Manag 8:77–89CrossRefGoogle Scholar
  33. 33.
    Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I (2013) Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention. Am J Cardiol 111:1570–1575CrossRefGoogle Scholar
  34. 34.
    Watanabe T, Ando K, Daidoji H, Otaki Y, Sugawara S, Matsui M, Ikeno E, Hirono O, Miyawaki H, Yashiro Y, Nishiyama S, Arimoto T, Takahashi H, Shishido T, Miyashita T, Miyamoto T, Kubota I, Investigators Cs (2017) A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol 70:537–544CrossRefGoogle Scholar
  35. 35.
    Sakamoto A, Saotome M, Hosoya N, Kageyama S, Yoshizaki T, Takeuchi R, Murata K, Nawada R, Onodera T, Takizawa A, Satoh H, Hayashi H (2016) Aberrant serum polyunsaturated fatty acids profile is relevant with acute coronary syndrome. Heart Vessels 31:1209–1217CrossRefGoogle Scholar
  36. 36.
    Stark AH, Crawford MA, Reifen R (2008) Update on alpha-linolenic acid. Nutr Rev 66:326–332CrossRefGoogle Scholar
  37. 37.
    Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, Tanizaki Y, Ibayashi S, Iida M, Kiyohara Y (2009) LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 40:382–388CrossRefGoogle Scholar
  38. 38.
    Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Investigators I-I (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387–2397CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Keisuke Nakabayashi
    • 1
    • 2
    • 3
  • Kentaro Jujo
    • 2
    • 3
    Email author
  • Yuho Furuki
    • 2
  • Issei Ishida
    • 3
  • Hiroshi Ando
    • 1
  • Minoru Shimizu
    • 1
  • Nobuhisa Hagiwara
    • 3
  • Katsumi Saito
    • 2
  1. 1.Department of CardiologyKasukabe Chuo General HospitalSaitamaJapan
  2. 2.Department of CardiologyNishiarai Heart Center HospitalTokyoJapan
  3. 3.Department of CardiologyTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations